5 recruiting, 3 not yet recruiting, 1 completed. 5 Phase 3, 2 Not applicable, 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Not yet recruiting 2, Recruiting 2, Completed 1 |
| Not applicable | 2 | Recruiting 2 |
| Phase 1 | 2 | Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow Heterozygous Familial Hypercholesterolemia (HeFH): new trials by email Literature Review of Heterozygous Familial Hypercholesterolemia (HeFH) trials Research Report on Heterozygous Familial Hypercholesterolemia (HeFH)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Long-Term Efficacy and Safety of Lerodalcibep in Children and Adolescents With Familial Hypercholesterolemia Lerodalcibep - Heterozygous Familial Hypercholesterolemia (HeFH) | Phase 3 | Not yet recruiting | LIB Therapeutics LLC | 150 | 2027-01-20 | 2026-08-25 |
| EDIT-401 in Adults Who Require Additional Lowering of Low-Density Lipoprotein Cholesterol (LDL-C) Drug: EDIT-401, Placebo - Heterozygous Familial Hypercholesterolemia (HeFH) | Phase 1 / Phase 2 | Not yet recruiting | Editas Medicine, Inc. | 56 | 2026-11-01 | 2026-10-26 |
| "Detection and Follow-up of Coronary Lesions in HeFH (DESTINY-FH Study)" Coronary computed tomography angiography - Heterozygous Familial Hypercholesterolemia (HeFH) | Not applicable | Recruiting | Assistance Publique - Hôpitaux de Paris | 300 | 2026-06-19 | 2026-06-24 |
| QLC7401 in Participants With Heterozygous Familial Hypercholesterolemia (HeFH) QLC7401 Injection, Placebo - Heterozygous Familial Hypercholesterolemia (HeFH) | Phase 3 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 120 | 2026-05-01 | 2026-03-04 |
| A Study to Evaluate the SYH2053 Injection in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) SYH2053 Injection, Placebo Injection - Heterozygous Familial Hypercholesterolemia (HeFH) | Phase 3 | Recruiting | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 135 | 2026-03-31 | 2026-07-08 |
| The ORIGIN-FH Study Screening for FH - Heterozygous Familial Hypercholesterolemia (HeFH), Homozygous Familial Hypercholesterolemia (HoFH) | Not applicable | Recruiting | University of Wisconsin, Madison | 70 | 2026-02-14 | 2026-10-13 |
| A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029) Enlicitide Decanoate, Placebo - Heterozygous Familial Hypercholesterolemia (HeFH) | Phase 2 / Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 153 | 2025-08-21 | 2026-10-07 |
| A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias CTX310 - Cardiovascular, Metabolic Disease | Phase 1 | Recruiting | CRISPR Therapeutics AG | 90 | 2024-06-21 | 2026-09-18 |
| A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050) Anacetrapib, Placebo for anacetrapib - Heterozygous Familial Hypercholesterolemia (HeFH) | Phase 3 | Completed | Merck Sharp & Dohme LLC | 68 | 2013-05-01 | 2016-04-25 |
Coronary Artery Disease (2) · Dyslipidemias (2) · Homozygous Familial Hypercholesterolemia (2) · Hypercholesterolemia (2) · Hyperlipoproteinemia Type II (2) · Lipid Metabolism Disorders (2) · Metabolic Diseases (2) · Atherosclerosis (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Genetic Diseases, Inborn (1) · Hyperlipidemias (1) · Hyperlipoproteinemia Type V (1) · Hyperlipoproteinemias (1) · Hypertriglyceridemia (1) · Lipid Metabolism, Inborn Errors (1)
Arterial Occlusive Diseases (2) · Arteriosclerosis (2) · Cardiovascular Diseases (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Coronary Disease (2) · Genetic Diseases, Inborn (2) · Heart Diseases (2) · Hyperlipidemias (2) · Hyperlipoproteinemias (2) · Lipid Metabolism, Inborn Errors (2) · Metabolism, Inborn Errors (2) · Myocardial Ischemia (2) · Nutritional and Metabolic Diseases (2) · Vascular Diseases (2) · Dyslipidemias (1)
MK-0616 (1) · Mass Screening (1) · anacetrapib (1)
Merck Sharp & Dohme LLC (2) · Assistance Publique - Hôpitaux de Paris (1) · CRISPR Therapeutics AG (1) · CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (1) · Editas Medicine, Inc. (1) · LIB Therapeutics LLC (1) · Qilu Pharmaceutical Co., Ltd. (1) · University of Wisconsin, Madison (1)
Australia (3) · New Zealand (3) · United States (3) · China (2) · France (2) · United Kingdom (2) · Belgium (1) · Brazil (1) · Chile (1) · Colombia (1) · Czechia (1) · Finland (1) · Germany (1) · India (1) · Israel (1)